Rani Therapeutics Holdings Inc - Ordinary Shares Class A Forecast, price target & analysts
Rani Therapeutics Holdings Inc - Ordinary Shares Class A Target price 2025 - Analyst rating & recommendation
Rani Therapeutics Holdings Inc - Ordinary Shares Class A Classifications & Recommendation:
Rani Therapeutics Holdings Inc - Ordinary Shares Class A Price Target
| Target Price | $10.86 |
| Price | $1.30 |
| Potential |
735.17%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Rani Therapeutics Holdings Inc - Ordinary Shares Class A 2026 .
The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A target price is $10.86.
This is
735.17%
register free of charge
$14.00
976.92%
register free of charge
$8.00
515.38%
register free of charge
|
|
| A rating was issued by 6 analysts: 6 Analysts recommend Rani Therapeutics Holdings Inc - Ordinary Shares Class A to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rani Therapeutics Holdings Inc - Ordinary Shares Class A stock has an average upside potential 2026 of
735.17%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.03 | 0.25 |
| 75.73% | ||
| EBITDA Margin | -4,715.53% | -21,120.40% |
| 347.89% | ||
| Net Margin | -3,407.91% | -9,560.98% |
| 180.55% |
4 Analysts have issued a sales forecast Rani Therapeutics Holdings Inc - Ordinary Shares Class A 2025 . The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Rani Therapeutics Holdings Inc - Ordinary Shares Class A 2025 . The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Rani Therapeutics Holdings Inc - Ordinary Shares Class A Analysts have issued a net profit forecast 2025. The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.05 | -0.72 |
| 21.05% | 31.43% | |
| P/E | negative | |
| EV/Sales | 186.52 |
2 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast for earnings per share. The average Rani Therapeutics Holdings Inc - Ordinary Shares Class A EPS is
This results in the following potential growth metrics and future valuations:
Rani Therapeutics Holdings Inc - Ordinary Shares Class A...
Current Rani Therapeutics Holdings Inc - Ordinary Shares Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 18 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
